References
- Cao W, He L, Liu W, Huang Z, Cheng Z. (2006). Determination of AKF-PD in whole blood of rat by HPLC-UV. J Chromatogr B, 833:257–9.
- Tao L, Hu G. (2008). 1-(Substituted phenyl)-5-methyl-2-(1H) pyridone in the manufacture of medicaments for treating fibrosis in organs or tissues, Patent No. EP1878428A, Application No. 06722303.2.
- Saenger W. (1980). Cyclodextrin inclusion compounds in research and laboratory. Angew Chem Int Ed Engl, 19:344–62.
- Szejtli J. (1998). Introduction and general overview of cyclodextrin chemistry. Chem Rev, 98:1743–54.
- Uekama K, Hirayama F, Irie T. (1998). Cyclodextrin drug carrier systems. Chem Rev, 98:2045–76.
- Cortes ME, Sinisterra RD, Avilacampos MJ, Tortamano N, Rocha RG. (2001). The chlorhexidine: β-cyclodextrin inclusion compound: Preparation, characterization and microbiological evaluation. J Incl Phenom Macrocycl Chem, 40:297–302.
- Brewster ME, Anderson WR, Meinsma D, Moreno D. (1997). Intravenous and oral pharmacokinetic evaluation of a 2.-hydroxypropyl-b-cyclodextrin-based formulation of carbamazepine in the dog: Comparison with commercially available tablets and suspensions. J Pharm Sci, 86:335–9.
- Sarah G, Robert CS. (2005). 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology review. Food Chem Toxicol, 43:1451–9.
- Farcas A, Jarrouxb N, Farcas A-M, Harabagiua V, Gueganb P. (2006). Synthesis and characterization of furosemide complex in β-cyclodextrin. Dig J Nanomater Biostruct, 1:55–60.
- Higuchi T, Connors KA. (1965). Phase solubility techniques. Adv Anal Chem Instrum, 4:117–212.
- Ribeiro L, Veiga F. (2002). Complexation of vinpocetine with cyclodextrins in the presence or absence of polymers: Binary and ternary complexes preparation and characterization. J Incl Phenom Macrocycl Chem, 44:251–6.
- Liu L, Zhu S. (2006). Preparation and characterization of inclusion complexes of prazosin hydrochloride with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. J Pharm Biomed Anal, 40:122–7.
- Veiga F, Teixeira-Dias JJC, Kedzierewicz F, Sousa A, Maincent P. (1996). Inclusion complexation of tolbutamide with β-cyclodextrin and 2-hydroxypropyl-β-cyclodextrin. Int J Pharm, 129:63–71.
- Marques HC, Hadgraft J, Kllaway I. (1990). Studies of cyclodextrin inclusion complexes I: The salbutamol-cyclodextrin complex as studies by phase solubility and DSC. Int J Pharm, 63:259–66.
- Kohata S, Jyodi K, Ohyoshi A. (1993). Thermal decomposition of cyclodextrins (α-, β-, γ-, and modified β-CyD) and of metal-(β-CyD) complexes in the solid phase. Thermochim Acta, 217:187–98.
- Beraldo H, Sinisterra RD, Teixeira LR, Vieira RP, Dorettob MC. (2002). An effective anticonvulsant prepared following a host–guest strategy that uses hydroxypropyl-β-cyclodextrin and benzaldehyde semicarbazone. Biochem Biophys Res Commun, 296:241–6.
- Damian F, Blaton N, Naesens L, Balzarini J, Kinget R, Augustijns P, Van Der Mooter G. (2000). Physicochemical characterization of solid dispersion of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. Eur J Pharm Sci, 10:311–22.
- Moyano JR, Arias-Blanco MJ, Gines JM, Giordano F. (1997). Solid-state characterization and dissolution characteristics of gliclazide-β-cyclodextrin inclusion complex. Int J Pharm, 148:211–17.
- Veiga F, Fernandes C, Maincent P. (2001). Influence of the preparation method on the physicochemical properties of tolbutamide/cyclodextrin binary system. Drug Dev Ind Pharm, 27:523–32.